Metformin-induced anticancer activities: recent insights
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Metformin is a widely used antidiabetic drug, and there is evidence among diabetic patients that metformin is a chemopreventive agent against multiple cancers. There is also evidence in human studies that metformin is a cancer chemotherapeutic agent, and several clinical trials that use metformin alone or in combination with other drugs are ongoing.In vivo and in vitro cancer cell culture studies demonstrate that metformin induces both AMPK-dependent and AMPK-independent genes/pathways that result in inhibition of cancer cell growth and migration and induction of apoptosis. The effects of metformin in cancer cells resemble the patterns observed after treatment with drugs that downregulate specificity protein 1 (Sp1), Sp3 and Sp4 or by knockdown of Sp1, Sp3 and Sp4 by RNA interference. Studies in pancreatic cancer cells clearly demonstrate that metformin decreases expression of Sp1, Sp3, Sp4 and pro-oncogenic Sp-regulated genes, demonstrating that one of the underlying mechanisms of action of metformin as an anticancer agent involves targeting of Sp transcription factors. These observations are consistent with metformin-mediated effects on genes/pathways in many other tumor types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“…both mitogen-activated protein kinase phosphatase 1 (MPK1) and MKP5 are induced by compounds (e.g. curcumin and rosiglitazone) (Nonn et al., 2007; Jan et al., 2009; Chen et al., 2011) that also decrease Sp TFs (Jutooru et al., 2010a; Gandhy et al., 2012), and we observed that metformin also…”
BackgroundOWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 1×
“Inhibition of mitochondrial complex 1 Inhibition of complex 1 can lead to multiple effects including AMPK activation (El-Mir et al., 2000; Owen et al., 2000; Brunmair et al., 2004; Hinke et al., 2007; Wheaton et al., 2014; Boukalova et al., 2016; Hawley et al., 2016)”
BackgroundBailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632 · cited 1×
“Figure 1 illustrates some of the health promoting, chemopreventive and chemotherapeutic effects of metformin, which include diabetes, preeclampsia, liver and kidney diseases, cardiovascular diseases, mortality and aging, multiple sclerosis, polycystic ovary disease, modulation of gut microorganisms and metabolites, er…”
BackgroundEl-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 1×
“Inhibition of mitochondrial complex 1 Inhibition of complex 1 can lead to multiple effects including AMPK activation (El-Mir et al., 2000; Owen et al., 2000; Brunmair et al., 2004; Hinke et al., 2007; Wheaton et al., 2014; Boukalova et al., 2016; Hawley et al., 2016)”
BackgroundMetformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 2×
“Another study showed that metformin non-competitively inhibits the redox shuttle enzyme glycerophosphate dehydrogenase, and this also results in decreased hepatic gluconeogenesis, which contributes to the antidiabetic activity of metformin (Madiraju et al., 2014).”
BackgroundForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 1×
“It was suggested that the loss of ATP contributes to the inhibition of hepatic gluconeogenesis, and this response is AMPK and LKB1 independent (Foretz et al., 2010).”
BackgroundMetformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
Wheaton, W. W., Weinberg, S. E., Hamanaka, R. B., Soberanes, S., Sullivan, L. B., Anso, E., Glasauer, A., Dufour, E., Mutlu, G. M., Budigner, G. S., et al. (2014) · eLife · doi:10.7554/elife.02242 · Cited by 1,105 · cited 1×
“Inhibition of mitochondrial complex 1 Inhibition of complex 1 can lead to multiple effects including AMPK activation (El-Mir et al., 2000; Owen et al., 2000; Brunmair et al., 2004; Hinke et al., 2007; Wheaton et al., 2014; Boukalova et al., 2016; Hawley et al., 2016)”
BackgroundMetformin as a tool to target aging
Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.011 · Cited by 1,096 · cited 3×
“…2013; Bannister et al., 2014; Cheng et al., 2014; Guo et al., 2014; Bhat et al., 2015; Feng et al., 2015; Goldberg et al., 2015; Victor et al., 2015; Barzilai et al., 2016; Brownfoot et al., 2016; Negrotto et al., 2016; Crowley et al., 2017; Patel et al., 2017; Pollak, 2017; Wu et al.,…”
BackgroundMetformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
Thiazolidinediones, Like Metformin, Inhibit Respiratory Complex I
Brunmair, B., Staniek, K., Gras, F., Scharf, N., Althaym, A., Clara, R., Roden, M., Gnaiger, E., Nohl, H., Waldhäusl, W., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.4.1052 · Cited by 521
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Bannister, C. A., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., & Currie, C. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12354 · Cited by 356 · cited 2×
“Figure 1 illustrates some of the health promoting, chemopreventive and chemotherapeutic effects of metformin, which include diabetes, preeclampsia, liver and kidney diseases, cardiovascular diseases, mortality and aging, multiple sclerosis, polycystic ovary disease, modulation of gut microorganisms and metabolites, er…”
BackgroundThe Diabetes Prevention Program Research Group (2005) · Diabetes · doi:10.2337/diabetes.54.5.1566 · Cited by 333 · cited 2×
“Figure 1 illustrates some of the health promoting, chemopreventive and chemotherapeutic effects of metformin, which include diabetes, preeclampsia, liver and kidney diseases, cardiovascular diseases, mortality and aging, multiple sclerosis, polycystic ovary disease, modulation of gut microorganisms and metabolites, er…”
BackgroundRomero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253 · cited 5×
“A recent review of metformin by Romero and coworkers (Romero et al., 2017) pointed out that metformin is rapidly gaining status as ‘the aspirin of the 21st century’, and its use has been associated with improvements in or prevention of many diseases.”
BackgroundInfluentialVazquez-Martin, A., Oliveras-Ferraros, C., & Menendez, J. A. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7499 · Cited by 250 · cited 3×
“, 2013); and also ErbB2 in breast cancer cells (Vazquez-Martin et al., 2009).”
BackgroundRozengurt, E., Sinnett-Smith, J., & Kisfalvi, K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2229 · Cited by 247 · cited 1×
“Metformin and related biquanides are highly effective anticancer agents in pancreatic cancer cells (Kisfalvi et al., 2009; Rozengurt et al., 2010; Kim et al., 2011; Bao et al., 2012; Gou et al., 2013; Karnevi et al., 2013; Lonardo et al., 2013; Sinnett-Smith et al., 2013; Soares et al., 2013; Li et al., 2017; Rajeshku…”
BackgroundGuo, M., Mi, J., Jiang, Q., Xu, J., Tang, Y., Tian, G., & Wang, B. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12265 · Cited by 225 · cited 2×
“Figure 1 illustrates some of the health promoting, chemopreventive and chemotherapeutic effects of metformin, which include diabetes, preeclampsia, liver and kidney diseases, cardiovascular diseases, mortality and aging, multiple sclerosis, polycystic ovary disease, modulation of gut microorganisms and metabolites, er…”
BackgroundBrownfoot, F. C., Hastie, R., Hannan, N. J., Cannon, P., Tuohey, L., Parry, L. J., Senadheera, S., Illanes, S. E., Kaitu’u-Lino, T. J., & Tong, S. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.12.019 · Cited by 222 · cited 2×
“Figure 1 illustrates some of the health promoting, chemopreventive and chemotherapeutic effects of metformin, which include diabetes, preeclampsia, liver and kidney diseases, cardiovascular diseases, mortality and aging, multiple sclerosis, polycystic ovary disease, modulation of gut microorganisms and metabolites, er…”
BackgroundNegrotto, L., Farez, M. F., & Correale, J. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4807 · Cited by 198 · cited 2×
“Figure 1 illustrates some of the health promoting, chemopreventive and chemotherapeutic effects of metformin, which include diabetes, preeclampsia, liver and kidney diseases, cardiovascular diseases, mortality and aging, multiple sclerosis, polycystic ovary disease, modulation of gut microorganisms and metabolites, er…”
BackgroundBayraktar, S., Hernadez‐Aya, L. F., Lei, X., Meric‐Bernstam, F., Litton, J. K., Hsu, L., Hortobagyi, G. N., & Gonzalez‐Angulo, A. M. (2012) · Cancer · doi:10.1002/cncr.26439 · Cited by 176 · cited 1×
“By contrast, one study showed that metformin did not affect survival of triple negative breast cancer patients (Bayraktar et al., 2012), and another report showed no survival benefits for breast cancer patients using metformin (Oppong et al., 2014).”
ResultType 2 Diabetes and Antidiabetic Medications in Relation to Dementia Diagnosis
Cheng, C., Lin, C.-H., Tsai, Y.-W., Tsai, C.-J., Chou, P.-H., & Lan, T.-H. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu073 · Cited by 167 · cited 2×
“Figure 1 illustrates some of the health promoting, chemopreventive and chemotherapeutic effects of metformin, which include diabetes, preeclampsia, liver and kidney diseases, cardiovascular diseases, mortality and aging, multiple sclerosis, polycystic ovary disease, modulation of gut microorganisms and metabolites, er…”
BackgroundWu, L., Zhu, J., Prokop, L. J., & Murad, M. H. (2015) · Scientific Reports · doi:10.1038/srep10147 · Cited by 144 · cited 2×
“, 2017), and this included one report which was a meta-analysis of 265 studies (Wu et al., 2015).”
BackgroundNair, V., Sreevalsan, S., Basha, R., Abdelrahim, M., Abudayyeh, A., Rodrigues Hoffman, A., & Safe, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.592576 · Cited by 129 · cited 7×
“Knockdown of Sp1, Sp3 and Sp4 by RNAi gave similar results, thus linking metformin-mediated inhibition of mTOR to Sp downregulation by this drug.”
BackgroundInfluentialSelf-citationPathi, S., Jutooru, I., Chadalapaka, G., Nair, V., Lee, S.-O., & Safe, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048208 · Cited by 127 · cited 1×
“…et al., 2007, 2011; Chadalapaka et al., 2008, 2012, 2013; Jutooru et al., 2010a,b,c, 2014; Basha et al., 2011; Gandhy et al., 2012; Liu et al., 2012; Pathi et al., 2012, 2014, 2011a,b; Sreevalsan and Safe, 2013; Hedrick et al., 2015, 2017; Kasiappan et al., 2016; Safe and Kasiappan, 2016;…”
Self-citationThe effects of metformin on gut microbiota and the immune system as research frontiers
Pollak, M. (2017) · Diabetologia · doi:10.1007/s00125-017-4352-x · Cited by 98 · cited 3×
“Figure 1 illustrates some of the health promoting, chemopreventive and chemotherapeutic effects of metformin, which include diabetes, preeclampsia, liver and kidney diseases, cardiovascular diseases, mortality and aging, multiple sclerosis, polycystic ovary disease, modulation of gut microorganisms and metabolites, er…”
BackgroundMetformin and prostate cancer mortality: A meta-analysis
Stopsack, K. H., Ziehr, D. R., Rider, J. R., & Giovannucci, E. L. (2016) · Cancer Causes & Control · doi:10.1007/s10552-015-0687-0 · Cited by 72 · cited 1×
“A number of studies in diabetics with prostate cancer also showed that metformin decreased the incidence and/or mortality from prostate cancer (Yu et al., 2014; Deng et al., 2015; Hwang et al., 2015; Raval et al., 2015; Stopsack et al., 2016; Wang et al., 2016), whereas prostate cancer chemoprevention was not observed…”
BackgroundHe, X.-K., Su, T.-T., Si, J.-M., & Sun, L.-M. (2016) · Medicine · doi:10.1097/md.0000000000002749 · Cited by 59 · cited 1×
“(Garrett et al., 2012; Lee et al., 2012; Spillane et al., 2013; Fransgaard et al., 2016; He et al., 2016; Paulus et al., 2016; Ramjeesingh et al., 2016; Park et al., 2017), although one report observed protection in female but not male patients (Park et al.”
BackgroundMetformin induces degradation of cyclin D1 via AMPK/GSK3β axis in ovarian cancer
Gwak, H., Kim, Y., An, H., Dhanasekaran, D. N., & Song, Y. S. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22498 · Cited by 53
Feng, L., Lin, X.-F., Wan, Z.-H., Hu, D., & Du, Y.-K. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1041906 · Cited by 50 · cited 2×
“Figure 1 illustrates some of the health promoting, chemopreventive and chemotherapeutic effects of metformin, which include diabetes, preeclampsia, liver and kidney diseases, cardiovascular diseases, mortality and aging, multiple sclerosis, polycystic ovary disease, modulation of gut microorganisms and metabolites, er…”
BackgroundPerez-Lopez, F. R., Pasupuleti, V., Gianuzzi, X., Palma-Ardiles, G., Hernandez-Fernandez, W., & Hernandez, A. V. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.04.001 · Cited by 45 · cited 1×
“Meta-analysis of endometrial cancer studies reported that metformin decreased mortality (Perez-Lopez et al., 2017), and this was confirmed in other studies (Ko et al., 2014; Nevadunsky et al., 2014; Ezewuiro et al., 2016), including one indicating that diabetic patients only with…”
ResultVictor, V. M., Rovira-Llopis, S., Bañuls, C., Diaz-Morales, N., Lopez-Domenech, S., Escribano-López, I., Rios-Navarro, C., Alvarez, A., Gomez, M., Rocha, M., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.017 · Cited by 44 · cited 2×
“…2005; Goldberg et al., 2013; Bannister et al., 2014; Cheng et al., 2014; Guo et al., 2014; Bhat et al., 2015; Feng et al., 2015; Goldberg et al., 2015; Victor et al., 2015; Barzilai et al., 2016; Brownfoot et al., 2016; Negrotto et al., 2016; Crowley et al., 2017; Patel et al., 2017;…”
Background
Cited by
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
Metformin as an Anticancer Agent
Vancura, A., Bu, P., Bhagwat, M., Zeng, J., & Vancurova, I. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.07.006 · Cited by 274
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Zhang, E., Mohammed Al-Amily, I., Mohammed, S., Luan, C., Asplund, O., Ahmed, M., Ye, Y., Ben-Hail, D., Soni, A., Vishnu, N., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.008 · Cited by 171
“the chemopreventive action of metformin (Safe et al., 2018) may in part be exerted through the here reported VDAC1 inhibition.”
Background
Metadata
- Authors
- Safe, S., Nair, V., & Karki, K.
- Venue
- Biological Chemistry
- Publisher
- Walter de Gruyter GmbH
- Published
- 2018-03-28
- Volume
- 399
- Issue
- 4
- Pages
- 321-335
- ISSN
- 1431-6730 (ISSN-L)
- 1437-4315
- OpenAlex
- W2776639172
- Cited by
- 63
- References
- 33
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.